Induction of the detoxifying enzyme heme oxygenase-1 (HO-1) is a critical protective host response to cellular injury associated with inflammation and oxidative stress. We previously found that HO-1 protein expression is reduced in brains of HIV-infected individuals with HIV-associated neurocognitive disorders (HAND) and in HIV-infected macrophages, where this reduction associates with enhanced glutamate release and neurotoxicity. Because HIV-infected macrophages are a small component of the cellular content of the brain, the reduction of macrophage HO-1 expression likely accounts for a small portion of brain HO-1 loss in HIV infection. We therefore investigated the contribution of astrocytes, the major pool of brain HO-1. We identified immunoproteasome-mediated HO-1 degradation in astrocytes as a second possible mechanism of brain HO-1 loss in HIV infection. We demonstrate that prolonged exposure of human fetal astrocytes to interferon-gamma 
| I N T R O D U C T I O N
We recently identified decreased expression of the phase II detoxifying enzyme heme oxygenase-1 (HO-1) in the brain prefrontal cortex of individuals with HIV-associated neurocognitive disorders (HAND), a spectrum of neurocognitive impairment that is diagnosed using neuropsychological testing and functional status assessments, and we further showed that HO-1 loss is linked to glutamate dysregulation in cultured HIV-infected macrophages (Gill et al., 2014; Gill, Kovacsics, Vance, Collman, & Kolson, 2015) . The heme oxygenase family consists of two expressed isoforms, HO-1 and HO-2, each of which catalyzes the degradation of free heme and generates equimolar amounts of carbon monoxide, bilirubin, and iron (Bauer, Huse, Settmacher, & Claus, 2008; Ryter, Kvam, & Tyrrell, 2000; Ryter, Otterbein, Morse, & Choi, 2002) . The HO-1 isoform is highly inducible with limited basal expression in most cell types among which neurons may express the lowest levels (Ambegaokar & Kolson, 2014) , while the HO-2 isoform is constitutively expressed in all cell types, including neurons (Munoz-Sanchez & Chanez-Cardenas, 2014) . Induced expression of HO-1 serves a critical function in the host's response to acute cellular injury, including that resulting from inflammation and oxidative stress. (Ambegaokar & Kolson, 2014; Gozzelino, Jeney, & Soares, 2010; . The cytoprotective effects of HO-1 have been linked to its enzymatic degradation of the pro-oxidant heme and subsequent generation of carbon monoxide and bilirubin, which have antiinflammatory and antioxidant properties; nonenzymatic cytoprotective functions have also been proposed (Gozzelino et al., 2010; Hori et al., 2002; Lin et al., 2007) .
HO-1 expression is tightly controlled through transcriptional regulation by both repressive and activating factors associated with oxidative stress, including the antioxidant response activator, nuclear factor erythroid 2-related factor 2 (Nrf2) (Alam & Cook, 2007; Salinas et al., 2004) . Nrf2 binds to the antioxidant response element (ARE) present within the promoter of HO-1 (HMOX1) and other antioxidant genes, and induces expression of more than 200 cytoprotective and detoxifying effector genes, including NAD(P)H dehydrogenase [quinone] 1 (NQO1), and glutathione peroxidase 1 (GPX1) (Ishii et al., 2000) . The net effect of Nrf2-driven transcriptional responses is the promotion of cell survival through restoration of cellular homeostasis, redox stability, and removal of injurious products.
Our previous in vivo studies showed reduced HO-1 protein expression in brain specimens from patients with a clinical diagnosis of HAND as well as in patients with a pathological diagnosis of HIVencephalitis (HIVE) (Gill et al., 2015) . HIVE is characterized by the presence of HIV-infected cells in the brain parenchyma, accompanied by formation of multi-nucleated giant cells, microglial nodules, microgliosis, astrogliosis, and perivascular inflammation (Gelman, 2015) . This loss of HO-1 protein expression in the brain of HIV-infected individuals is not accompanied by a lower protein expression of other ARE proteins, including NQO1 and GPX1, which suggests that the loss of HO-1 protein in HIV infection is relatively selective among the ARE proteins.
This further suggests that transcriptional down-regulation of the ARE promoter element is not likely to be the driving force for the selective lowering of brain HO-1 in HAND (Cross et al., 2011; Gill et al., 2014) .
In contrast, our in vitro studies of HIV infection of macrophages (a major reservoir for HIV replication in the brain) showed that HIV replication results in selective reduction of both HO-1 RNA and protein expression; the parallel decrease in HO-1 RNA and protein suggests a transcriptional mechanism of HO-1 suppression that is relevant specifically to HIV infection of brain macrophages (Gill et al., 2015) . However, macrophages represent a relatively small fraction of the total cellular content of the brain and neurons express very little to no basal HO-1.
Astrocytes, which have detectable basal and rapidly inducible HO-1 expression, represent a large cellular pool of brain HO-1. We therefore sought to identify possible mechanisms of HIV-associated dysregulation of HO-1 expression in astrocytes, which are not a source of productive HIV replication (Boutet et al., 2001 ), but which could be modulated by inflammatory pathways triggered by HIV replication in brain macrophages.
Given the associations between HIV infection, brain prefrontal cortex HO-1 protein loss and markers of immune activation, we hypothesized that HIV-driven neuroinflammation can dysregulate astrocyte HO-1 expression in HIV infected brain (Gill et al., 2014) .
We determined the effects of several HIV-relevant immune mediators, including TNFa, IFNg, and lipopolysaccharide (LPS) on heme oxygenase expression in primary human fetal astrocytes under conditions of both short-and long-term exposure, to mimic conditions of acute and chronic HIV brain infection relevant to HAND pathogenesis (Schrier et al., 2015) . We considered both transcriptional and post-transcriptional mechanisms for the selective HO-1 loss. (Schrier et al., 2015) . Thus, our studies have identified a plausible, novel mechanism of HO-1 loss in HIV-infected brain that is modulated by chronic IFNg-induction of immunoproteasome-mediated degradation in astrocytes. (Morgello et al., 2001; Nguyen, Soukup, & Gelman, 2010) . Among the 90 HIV-positive cases, 14 subjects had pathologically confirmed encephalitis (HIVE) and 76 subjects did not have HIVE (HIV 1 / HIVE -). NNTC site neuropathologists assigned the diagnosis of HIVE by the criteria of Budka et al. (1991) . The neurocognitive diagnosis of HAND was assigned by the supervising neuropsychologist according to the Frascati Criteria as reviewed by an experienced neurologist (Antinori et al., 2007; Woods et al., 2004) . Sixty-three percent of HIV-positive individuals were antiretroviral therapy (ART)-experienced. HIV-negative subjects were significantly older than HIV-positive subjects (6.6 years), but did not significantly differ from HIV-positive subjects in gender, ethnicity, race, or postmortem interval. Further details on demographic and clinical data of this cohort were described previously (Gill et al., 2014; Nguyen et al., 2010 School of Medicine. Astrocyte cultures were fed with astrocyte growth media (DMEM/F-12 supplemented with 15% FBS, 50 lg/ml Gentamicin, 5 lg/ml Fungizone, 2 mM L-glutamine, and 10 lg/ml insulin) and maintained at 378C and 5% CO 2 . The human U251 MG cell line, derived from human glioblstoma, was cultured in growth medium (DMEM supplemented with 10% FBS, 2 mM L-glutamine, 10 mM HEPES, 100 U/ml penicillin, and 100 lg/ml streptomycin) and maintained at 378C and 5% CO 2 . Stock solutions of purified LPS (SigmaAldrich), recombinant human TNFa (Peprotech), and recombinant human IFNg (Peprotech) were prepared in sterile phosphate buffered saline (PBS). Cells were exposed to vehicle (PBS), LPS (1 lg/ml), TNFa (10 ng/ml), and IFNg (10 ng/ml) alone or in combination for indicated lengths of time and medium and treatments were replaced every 3 days. Stock solutions of the cell-permeable proteasome inhibitor MG132 (Sigma-Aldrich) were prepared in sterile DMSO and cells were treated with MG132 (5 lM) 2 hours prior to and throughout pulsechase assays to inhibit proteasome activity. 
| Study approvals
Handling of NNTC-derived human autopsy specimens was in accordance with human subject protection protocols at participating institu- To further define the association between immunoproteasome expression and HIV infection we attempted to localize subunit expression using immunohistochemistry and indirect immunofluorescence labeling. LMP2 immunoreactivity in frontal white matter was increased 3.4 | IFNc induces expression of immunoproteasome subunits and reduces expression of constitutive proteasome subunits in astrocytes HO-1 protein is an established target of proteasome-mediated degradation (Boname et al., 2014; Lin, Chiang, & Chau, 2008; Lin, Lan, & Chau, 2013) , and proteasome function and composition is markedly influenced by IFNg (Stohwasser et al., 2000) . We therefore asked whether the loss of HO-1 protein in IFNg exposed astrocytes was associated with induction of the immunoproteasome. Accordingly, we determined the expression of the immunoproteasome regulatory 
| IFNc-driven modulation of proteasome subunit expression and HO-1 protein reduction is dosedependent
Given that we identified prolonged IFNg exposure as a unique cause of reduced HO-1 protein expression in astrocytes, we determined the effects of IFNg over a concentration range that includes those reported in the CSF of HIV-infected individuals (1-10 pg/ml) (Kamat et al., 2012) . The response of human fetal astrocytes to a prolonged exposure to IFNg appeared to be biphasic, with increased HO-1 protein expression observed up to 100 pg/ml, an apparent inflection point between 100 pg/ml and 1 ng/ml, and then a significant reduction in HO-1 protein at 10 ng/ml (Figure 6a and Supporting Information Figure 1A ). In contrast, IFNg consistently increased expression of both HO-2 and NQO1 proteins (Supporting Information Figure 1B ,C). At doses between 100 pg/ml and 1 ng/ml IFNg, the observed reduction in HO-1 protein was accompanied by a significant reduction in the expression of constitutive proteasome subunits b2, b5, and b1 ( Figure   6b and Supporting Information Fig 1D,E) . In contrast, immunoproteasome subunits PA28a, LMP7, and LMP2 were significantly increased starting at 10 pg/ml IFNg, with significantly enhanced induction observed at 1 ng/ml IFNg ( Figure 6b ,c and Supporting Information Figure 1E) . As reduced HO-1 protein was associated with induction of immunoproteasome subunits and concurrent loss of constitutive proteasome subunits, these data gave added support to the hypothesis that the replacement of constitutive proteasomes by immunoproteasomes is critical for IFNg-driven HO-1 protein loss in astrocytes.
| IFNc-driven modulation of proteasome subunit expression and HO-1 reduction is time-dependent
To assess the kinetics of immunoproteasome induction and constitutive proteasome loss associated with IFNg exposure, astrocytes were IFNg effects on expression of proteasome subunits and HO-1 are dose-dependent. Primary human fetal astrocytes were exposed to IFNg (0.1 pg/ml-25 ng/ml) for 15 days. Media and treatments were replaced every 3 days. Western blot densitometry quantification of (a) HO-1, (b) PA28a, (c) LMP7, and b5 protein expression relative to vehicle after normalization to b-tubulin. Data were log transformed and values represent mean 6 SEM (n 5 4 biological replicates) of the fold change from vehicle (dotted line). Statistical comparisons to vehicle were made by RM-ANOVA with post hoc Holm-Sidak test. *p < 0.05; **p < 0.01; ***p < 0.001; **** p < 0. exposed to IFNg (10 ng/ml) or vehicle continuously for up to 15 days.
We hypothesized that the loss of constitutive proteasome subunits would be slow given the relatively long half-life of constitutive proteasome complexes (5 days) and HO-1 protein expression would be decreased only at later time points associated with this progressive loss of constitutive proteasomes (Heink, Ludwig, Kloetzel, & Kruger, 2005; Khan et al., 2001; Tanaka & Ichihara, 1989) . HO-1 RNA expression was increased by day 9 and sustained through day 15 (Supporting Information Figure 2A ), however no significant increase in HO-1 protein was seen at any time point and HO-1 protein was significantly reduced at day 15 (Supporting Information Figure 2C,D) . In contrast, HO-2 RNA and protein were significantly increased by day 3 and this persisted through day 15 (Supporting Information Figure 2B ,C,E). Furthermore, the ARE protein NQO1 was significantly increased by IFNg at day 9 and this persisted through day 15 (Supporting Information Figure 2C ,F).
We thus concluded that the discordant effect of prolonged IFNg on HO-1 RNA and protein expression is relatively specific to HO-1.
The expression of both immunoproteasome and constitutive proteasome subunits also consistently changed with duration of IFNg exposure. Immunoproteasome subunits PA28a, LMP7, and LMP2 were increased by day 3 and remained elevated at each subsequent time point (Supporting Information Figure 2G ,I,J). PA28a expression remained at the same elevation achieved at day 3, while expression of LMP7 and LMP2 increased through day 6 and then remained at the same elevated level. In contrast, the constitutive proteasome subunits b2, b5, and b1were progressively reduced through day 15 (Supporting Information Figure 2H -J). The progressive loss of b5 and b1 at each time point suggests that the loss of these constitutive subunits combined with the increased expression of the immunoproteasome subunits may account for the reduction of HO-1 protein expression. This is consistent with previously reported IFNg-driven replacement of constitutive proteasomes by immunoproteasomes (Groettrup, Khan, Schwarz, & Schmidtke, 2001; Heink et al., 2005; Meiners, Keller, Semren, & Caniard, 2014; Rivett, Bose, Brooks, & Broadfoot, 2001; Tanaka, 2013) and it is further consistent with a role for the immunoproteasome in mediating HO-1 protein loss with IFNg treatment.
| IFNc increases the rate of HO-1 protein degradation mediated by proteasome-dependent mechanisms
Given the coordinated reduction in HO-1 protein expression and induction of immunoproteasomes with reciprocal loss of constitutive proteasomes in IFNg-exposed astrocytes, we hypothesized that HO-1 protein is degraded more rapidly by the immunoproteasome. To test this, we measured HO-1 protein half-life in astrocytic cells exposed to Representative phosphorimage used for densitometric quantification of radiolabeled FLAG-HO-1. Black arrows indicate radiolabeled FLAG-HO-1. (c) Degradation of HO-1 protein was determined by densitometric quantification of radiolabeled FLAG-HO-1 and are expressed as a percentage relative to time 0 within each independent experiment (n 5 3). Data represent mean 6 SEM. Protein half-life in vehicle and IFNg conditions (closed circles) was determined by one-phase exponential decay and rate of decay (k) was compared by Extra sum of squares F test. ***p < 0.001. The effects of MG-132 at each time point was analyzed by two-way RM-ANOVA with post hoc Holm-Sidak test (significance not shown in figure) . IFNg vs. IFNg1MG-132: p < 0.001 at all time points. PBS vs. PBS 1 MG-132: p < 0.01 at 8hr; p < 0.001 at 2, 4, and 12 hr [Color figure can be viewed at wileyonlinelibrary.com] protein expression was significantly increased, similar to our observations in primary fetal astrocytes (Supporting Information Figure 3) . Additionally, IFNg increased the expression of immunoproteasome subunits LMP7 and LMP2 and decreased expression of the corresponding constitutive b5 and b2 subunits (Supporting Information Figure 3) . Thus, the discordance between RNA and protein levels seen for HO-1, but not HO-2, and the shift to expression of immunoproteasomes after IFNg exposure in this cell line recapitulates the effects of prolonged IFNg seen in human primary fetal astrocytes.
We next determined the rate of FLAG-HO-1 degradation in transfected U-251 cells exposed to IFNg for 3 days using [ 
| DISCUSSION
The introduction of antiretroviral therapy (ART) has significantly transformed HIV infection from a uniformly lethal disease into a manageable chronic condition in which neurocognitive dysfunction persists in a significant proportion of ART-treated individuals (Broder, 2010; Heaton et al., 2011; Saylor et al., 2016; Simioni et al., 2010) . Despite abundant evidence implicating persistent inflammation and oxidative stress in the pathogenesis of HIV-associated neurocognitive disorders, the mechanisms by which these processes drive neurocognitive impairment in HIV-infected individuals remain incompletely understood (Babbe et al., 2000; Bandaru et al., 2007; Eden, Price, Spudich, Fuchs, Hagberg, & Gisslen, 2007) . We previously identified reduced HO-1 protein in HIVinfected brain as a host factor potentially contributing to HAND pathogenesis and we further suggested targeting HO-1 brain loss as an adjunctive neuroprotective strategy in ART-treated individuals (Gill et al., 2014 (Gill et al., , 2015 .
Our new data demonstrate that the decreased HO-1 protein expression in HIV-infected brain is accompanied by increased HO-1 RNA expression, suggesting a post-transcriptional mechanism of HIVmediated HO-1 protein loss, and we have identified enhanced immunoproteasome-mediated degradation of HO-1 in IFNg-exposed astrocytes as a potential mechanism of HO-1 loss in the HIV-infected brain. In both HIV-infected brain and in human astrocytes exposed to IFNg, we observed reduced HO-1 protein expression but did not detect reduced expression of other members of the ARE/Nrf2-driven family nor the ARE-independent heme oxygenase isoform HO-2 (Gill et al., 2014) , which suggests that HO-1 is selectively affected. Furthermore, this decrease in HO-1 protein was not accompanied by decreased HO-1 RNA expression in either HIV-infected brain or astrocytes exposed to IFNg in vitro. Additionally, we have previously demonstrated that HIV-infected subjects have increased brain expression of immunoproteasomes subunits (PA28a and LMP7) and that this increased expression associates with neurocognitive impairment, particularly with neuropsychological subtests associated with executive functioning and speed of processing (Nguyen et al., 2010) . We now show that IFNg treatment of primary human astrocytes increases expression of regulatory and catalytic immunoproteasome subunits (Cassol, Misra, Dutta, Morgello, & Gabuzda, 2014; Schrier et al., 2015) .
We examined effects of both acute (24 hours) and prolonged (15 days) exposure to immune activators associated with HIV infection of the brain because neurodegeneration associated with HIV infection is believed to progress over years, during which time persistent immune activation within the CNS is observed. The immune activators TNFa, LPS, and IFNg are elevated in HIV-infected individuals and associated with HAND, and each has been shown to modulate the expression of HO-1 after acute exposure in various cell types, although effects on HO-1 after prolonged exposure have not been clearly defined (Ambegaokar & Kolson, 2014; Ancuta et al., 2008; Brenchley et al., 2006; Griffin, 1997; Wagener et al., 2003; Wesselingh et al., 1997 produced by macrophages and T cells, is observed in serum, CSF, and brain parenchyma in HIV-infected individuals, including those receiving ART (Fuchs et al., 1989a,b; Griffin, McArthur, & Cornblath, 1991; Kamat et al., 2012; Shapshak et al., 2004) This apparent requirement for replacement of constitutive proteasomes by immunoproteasomes implies that the functional balance between activities of constitutive and immunoproteasome complexes influences HO-1 protein expression. Newly synthesized immunoproteasome subunits do not replace corresponding constitutive subunits within existing proteasome complexes; instead, they are preferentially incorporated over constitutive subunits into de novo complexes (Fruh, Gossen, Wang, Bujard, Peterson, & Yang, 1994; Heink et al., 2005; Nandi, Woodward, Ginsburg, Monaco, 1997) . Thus, modest induction of immunoproteasome subunits without concurrent loss of constitutive proteasomes is unlikely to dramatically shift the balance between constitutive proteasomes and immunoproteasomes (Aki et al., 1994) .
Although IFNg induces expression of immunoproteasome subunits, it does not suppress the expression of constitutive subunits, and thus it does not directly drive the loss of constitutive proteasome complexes Nandi, Jiang, & Monaco, 1996) . Increased incorporation of immunoproteasome subunits into nascent complexes effectively excludes constitutive subunits and leaves them vulnerable to rapid degradation in this "free" form (Heink et al., 2005; Murata, Yashiroda, & Tanaka, 2009) . As more immunoproteasome complexes are formed, the pool of pre-existing constitutive proteasome complexes is reduced through degradation, with a half-life of approximately 5 days that is unaffected by IFNg (Nandi et al., 1997) (Amadio et al., 2014; Boname et al., 2014; Cheng, Ku, & Siow, 2013; Leautaud & Demple, 2007; Lin et al., 2008 Lin et al., , 2013 Ma et al., 2013) . Intrinsic properties of the catalytic subunits of immunoproteasomes might directly promote HO-1 degradation, as immunoproteasomes show enhanced cleavage rates and increased preference for specific cleavage sites compared to constitutive proteasomes (Basler, Youhnovski, Van Den Broek, Przybylski, & Groettrup, 2004; Dahlmann, Ruppert, Kuehn, Merforth, & Kloetzel, 2000; Mishto et al., 2014; Raule, Cerruti, & Cascio, 2014; Zanker, Waithman, Yewdell, & Chen, 2013) . Alternatively, IFNg may regulate upstream components of the ubiquitin proteasome system to enhance immunoproteasome access to HO-1 protein. Recent work has shown that intramembrane cleavage of HO-1 by signal peptide peptidase (SPP) and ubiquitination by the E3 ubiquitin ligase TRC8 are critical for removal of the HO-1 tail anchor from the ER and subsequent proteasome-dependent degradation (Boname et al., 2014; Hsu et al., 2015; Lin et al., 2013) . Modulating effects of IFNg on the activity of SPP and TRC8 are not known, but these are potential mechanisms that may enhance degradation of HO-1 protein.
Our studies provide compelling evidence that enhanced degradation of HO-1 by immunoproteasomes within astrocytes may drive reduced expression of HO-1 protein in HIV-infected brain and they suggest that persistently elevated IFNg is a critical modulator linking chronic immune activation to the pathogenesis of HAND. When present at moderate levels and/or for brief periods, IFNg may exert beneficial effects during HIV infection through induction of HO-1 expression, which would be expected to limit inflammation and oxidative stress in various tissues. IFNg-mediated induction of immunoproteasomes has been suggested to be a beneficial host response that protects cells from proteotoxic stress and enhances the cellular capacity to degrade oxidized proteins accumulating as a result of inflammation and oxidative stress (Seifert et al., 2010) . Immunoproteasomes are thought to subserve a rapid and transient response to stress, exhibiting a faster rate of assembly and significantly shorter half-life than constitutive proteasomes (Heink et al., 2005) . Prolonged induction of immunoproteasomes may dysregulate the expression and/or degradation of cellular proteins other than HO-1, which could contribute to pathological processes. For example, studies suggest that immunoproteasomes enhance the production and presentation of antigenic peptides derived from myelin basic protein, suggesting similar effects on other endogenous proteins could contribute to autoimmune disorders (Belogurov et al., 2014 (Belogurov et al., , 2015 Kuzina et al., 2013) .
Our previous studies suggest that HO-1-inducing therapies could offer a therapeutic approach for neuroprotection in HIV-infected individuals and perhaps other neurodegenerative diseases. We previously showed that HIV infection of monocyte-derived macrophages drives HO-1 protein and RNA loss in a time-dependent manner and this is associated with neurotoxic levels of extracellular glutamate (Gill et al., 2015) . Induction of HO-1 expression in HIV-infected macrophages reduces extracellular levels of glutamate and associated neurotoxicity (Gill et al., 2014) 
